- Home
- LCID vs HALO Comparison
LCID vs HALO Comparison
Compare LCID & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCID
- HALO
- Stock Information
- Founded
- LCID 2007
- HALO 1998
- Country
- LCID United States
- HALO United States
- Employees
- LCID N/A
- HALO N/A
- Industry
- LCID Auto Manufacturing
- HALO Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- LCID Consumer Discretionary
- HALO Health Care
- Exchange
- LCID Nasdaq
- HALO Nasdaq
- Market Cap
- LCID 5.8B
- HALO 6.4B
- IPO Year
- LCID N/A
- HALO N/A
- Fundamental
- Price
- LCID $2.01
- HALO $45.65
- Analyst Decision
- LCID Hold
- HALO Buy
- Analyst Count
- LCID 10
- HALO 9
- Target Price
- LCID $3.43
- HALO $61.11
- AVG Volume (30 Days)
- LCID 66.1M
- HALO 1.7M
- Earning Date
- LCID 11-07-2024
- HALO 10-31-2024
- Dividend Yield
- LCID N/A
- HALO N/A
- EPS Growth
- LCID N/A
- HALO 61.71
- EPS
- LCID N/A
- HALO 3.02
- Revenue
- LCID $730,510,000.00
- HALO $947,355,000.00
- Revenue This Year
- LCID $40.55
- HALO $23.36
- Revenue Next Year
- LCID $96.14
- HALO $15.15
- P/E Ratio
- LCID N/A
- HALO $15.10
- Revenue Growth
- LCID 4.98
- HALO 21.35
- 52 Week Low
- LCID $1.93
- HALO $33.15
- 52 Week High
- LCID $5.31
- HALO $65.53
- Technical
- Relative Strength Index (RSI)
- LCID 28.13
- HALO 30.20
- Support Level
- LCID $2.12
- HALO $50.01
- Resistance Level
- LCID $2.33
- HALO $62.13
- Average True Range (ATR)
- LCID 0.15
- HALO 2.60
- MACD
- LCID 0.01
- HALO -0.50
- Stochastic Oscillator
- LCID 12.90
- HALO 0.15
About LCID Lucid Group Inc.
Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
About HALO Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with unmet medical needs, with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. The company's operations are based in the United States, with minimal long-lived assets located internationally.